182 related articles for article (PubMed ID: 32776380)
41. Linezolid-Induced Lactic Acidosis Sets Stage for Surgery to Rule Out Mesenteric Ischemia: A Case Report.
Belani K; Leibowitz A; Bose S
A A Pract; 2018 Aug; 11(4):93-95. PubMed ID: 29634533
[TBL] [Abstract][Full Text] [Related]
42. Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case-control study.
Chen C; Li Y; Yu J; Qian S
Clin Transl Oncol; 2022 Mar; 24(3):540-545. PubMed ID: 34716540
[TBL] [Abstract][Full Text] [Related]
43. A retrospective test for a possible relationship between linezolid-induced thrombocytopenia and hyponatraemia.
Tanaka R; Suzuki Y; Morinaga Y; Iwao M; Takumi Y; Hashinaga K; Tatsuta R; Hiramatsu K; Kadota JI; Itoh H
J Clin Pharm Ther; 2021 Apr; 46(2):343-351. PubMed ID: 33016566
[TBL] [Abstract][Full Text] [Related]
44. Linezolid as a Potentially Effective Drug for the Treatment of Multidrug-Resistant Tuberculosis in Japan.
Yi L; Yoshiyama T; Okumura M; Morimoto K; Sasaki Y; Shiraishi Y; Ogata H; Mitarai S
Jpn J Infect Dis; 2017 Jan; 70(1):96-99. PubMed ID: 27000461
[TBL] [Abstract][Full Text] [Related]
45. A severe linezolid-induced rhabdomyolysis and lactic acidosis in Leigh syndrome.
Primiano G; Servidei S
J Inherit Metab Dis; 2021 Jan; 44(1):4-5. PubMed ID: 33155302
[No Abstract] [Full Text] [Related]
46. Thrombocytopenia with Tedizolid and Linezolid.
Lee EY; Caffrey AR
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038274
[TBL] [Abstract][Full Text] [Related]
47. Adverse event notifications implicating metformin with lactic acidosis in Australia.
Huang W; Castelino RL; Peterson GM
J Diabetes Complications; 2015; 29(8):1261-5. PubMed ID: 26104729
[TBL] [Abstract][Full Text] [Related]
48. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
49. [Linezolid-induced lactic acidosis - a brief overview with a case report].
Pazderkovák J; Kotora V; Dlouhý P; Bartoš H
Klin Mikrobiol Infekc Lek; 2019 Sep; 25(3):92-96. PubMed ID: 31904104
[TBL] [Abstract][Full Text] [Related]
50. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.
Abe J; Umetsu R; Kato Y; Ueda N; Nakayama Y; Suzuki Y; Suzuki T; Nagasawa H; Kinosada Y; Nakamura M
Int J Med Sci; 2015; 12(4):312-21. PubMed ID: 25897292
[TBL] [Abstract][Full Text] [Related]
52. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
Fujimoto M; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
[TBL] [Abstract][Full Text] [Related]
53. Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: A retrospective cohort analysis: Effectiveness of linezolid in the elderly.
Takada H; Hifumi T; Nishimoto N; Kanemura T; Yoshioka H; Okada I; Kiriu N; Inoue J; Koido Y; Kato H
Am J Emerg Med; 2017 Feb; 35(2):245-248. PubMed ID: 27832976
[TBL] [Abstract][Full Text] [Related]
54. Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress.
Wang TL; Guo DH; Bai Y; Wen K; Han WY; Wang R
Clin Drug Investig; 2016 Jan; 36(1):67-75. PubMed ID: 26507619
[TBL] [Abstract][Full Text] [Related]
55. Mitochondrial toxicity induced by linezolid causing lactic acidosis.
Sharma K; Keri VC; Kumar TP; Sethi P; Dass J; Mishra RK
Trop Doct; 2023 Apr; 53(2):315-316. PubMed ID: 36890727
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
McConeghy KW; Bress A; Qato DM; Wing C; Nutescu EA
Pharmacotherapy; 2014 Jun; 34(6):561-9. PubMed ID: 24644100
[TBL] [Abstract][Full Text] [Related]
57. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
58. In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates.
Beitdaghar M; Ahmadrajabi R; Karmostaji A; Saffari F
Wien Med Wochenschr; 2019 Jun; 169(9-10):215-221. PubMed ID: 28924925
[TBL] [Abstract][Full Text] [Related]
59. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis.
Lifan Z; Sainan B; Feng S; Siyan Z; Xiaoqing L
Int J Tuberc Lung Dis; 2019 Dec; 23(12):1293-1307. PubMed ID: 31931914
[No Abstract] [Full Text] [Related]
60. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
